Primary Myelofibrosis Market Report and Forecast 2025-2034
Description
The primary myelofibrosis market size was valued at USD 877.43 Million in 2024, driven by the increasing prevalence of myelofibrosis across the 7 major markets. The market size is anticipated to grow at a CAGR of 5.70% during the forecast period of 2025-2034 to achieve a value of USD 1527.43 Million by 2034.
Primary Myelofibrosis: Introduction
Myelofibrosis is a rare blood cancer where scar tissue forms in your bone marrow. It is a type of chronic leukemia that involves too many abnormal blood cells being made. Eventually, these cells can replace normal cells. Treatment goals mainly involve managing symptoms and conditions that arise, including anemia and an enlarged spleen. Primary myelofibrosis is a condition characterized by the buildup of scar tissue (fibrosis) in the bone marrow, the tissue that produces blood cells. Because of the fibrosis, the bone marrow is unable to make enough normal blood cells. The shortage of blood cells causes many of the signs and symptoms of primary myelofibrosis.
Primary Myelofibrosis Market Analysis
The market growth is driven by the increased prevalence of primary myelofibrosis. The key market players are increasing their efforts toward discovering and producing the best and most effective treatment options to increase life expectancy worldwide. The recent developments in the field of myelofibrosis have been exhibited by the FDA approval of Ojjaara (momelotinib) by GSK plc and the Fast Track Designation granted to selinexor by Karyopharm Therapeutics Inc., are anticipated to have a significant positive impact on the growth of the primary myelofibrosis market.
People with myelofibrosis often develop anemia, which is a problem resulting in more than 30% of patients discontinuing the treatment. Recently, the FDA has approved a new medicine called Ojjaara. This once-a-day pill targets JAK1, JAK2, and ACVR1. This medicine has exclusively been made for those with intermediate or high-risk myelofibrosis, including both primary and secondary types. By effectively targeting key disease manifestations such as anemia, constitutional symptoms, and splenomegaly, Ojjaara is poised to offer a comprehensive therapeutic solution and boost the primary myelofibrosis market growth.
Furthermore, the Fast Track Designation granted to selinexor exemplifies the industry's commitment to advancing innovative therapies for myelofibrosis patients, reflecting a proactive approach to expedite the development of potential treatments. As ongoing clinical trials explore various therapeutic options, the forecast period is expected to witness a surge in FDA-approved treatments for myelofibrosis, thereby propelling the growth of the primary myelofibrosis market. This increase in approved treatments not only expands the spectrum of available therapeutic interventions but also addresses the unmet needs of patients, contributing to the overall advancement of myelofibrosis care.
Primary Myelofibrosis Market Segmentations
“Primary Myelofibrosis Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
The increasing emphasis on research and development activities by key players is expected to potentially create lucrative opportunities for primary myelofibrosis treatment market growth. Primary myelofibrosis is a rare disease, with an annual incidence of approximately 0.5-1.5 cases per 100,000 individuals in the United States. The incidence rate of myelofibrosis ranged from 0.1 to 1 case per 100,000 per year. The additional market growth can be attributed to the increasing awareness regarding Primary Myelofibrosis (PMF) treatment and the rise in the number of patients is also poised to result in increased production of more effective and targeted treatment drugs and JAK inhibitors.
The healthcare sector has been improving, and favorable government initiatives, reimbursement policies, and changing dietary patterns are collectively contributing to the primary myelofibrosis market growth. These factors, along with the busy lifestyle, are contributing to the growth of the market. Additionally, the market is expected to grow further due to increased investments in research and development activities aimed at developing precise treatments for myelofibrosis in the forecast period.
Geographically, North America is currently dominating the regional market and is expected to drive market growth in the forecast period as well. The market growth is expected to be driven by the increased research and development activities by key players in order to develop more effective and targeted treatment options for the patients, resulting in better patient outcomes. Also, the presence of some of the key players in the region is also propelling the market growth.
Primary Myelofibrosis Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Primary Myelofibrosis: Introduction
Myelofibrosis is a rare blood cancer where scar tissue forms in your bone marrow. It is a type of chronic leukemia that involves too many abnormal blood cells being made. Eventually, these cells can replace normal cells. Treatment goals mainly involve managing symptoms and conditions that arise, including anemia and an enlarged spleen. Primary myelofibrosis is a condition characterized by the buildup of scar tissue (fibrosis) in the bone marrow, the tissue that produces blood cells. Because of the fibrosis, the bone marrow is unable to make enough normal blood cells. The shortage of blood cells causes many of the signs and symptoms of primary myelofibrosis.
Primary Myelofibrosis Market Analysis
The market growth is driven by the increased prevalence of primary myelofibrosis. The key market players are increasing their efforts toward discovering and producing the best and most effective treatment options to increase life expectancy worldwide. The recent developments in the field of myelofibrosis have been exhibited by the FDA approval of Ojjaara (momelotinib) by GSK plc and the Fast Track Designation granted to selinexor by Karyopharm Therapeutics Inc., are anticipated to have a significant positive impact on the growth of the primary myelofibrosis market.
People with myelofibrosis often develop anemia, which is a problem resulting in more than 30% of patients discontinuing the treatment. Recently, the FDA has approved a new medicine called Ojjaara. This once-a-day pill targets JAK1, JAK2, and ACVR1. This medicine has exclusively been made for those with intermediate or high-risk myelofibrosis, including both primary and secondary types. By effectively targeting key disease manifestations such as anemia, constitutional symptoms, and splenomegaly, Ojjaara is poised to offer a comprehensive therapeutic solution and boost the primary myelofibrosis market growth.
Furthermore, the Fast Track Designation granted to selinexor exemplifies the industry's commitment to advancing innovative therapies for myelofibrosis patients, reflecting a proactive approach to expedite the development of potential treatments. As ongoing clinical trials explore various therapeutic options, the forecast period is expected to witness a surge in FDA-approved treatments for myelofibrosis, thereby propelling the growth of the primary myelofibrosis market. This increase in approved treatments not only expands the spectrum of available therapeutic interventions but also addresses the unmet needs of patients, contributing to the overall advancement of myelofibrosis care.
Primary Myelofibrosis Market Segmentations
“Primary Myelofibrosis Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
- Spinocerebellar Primary Myelofibrosiss
- Primary Myelofibrosis-Telangiectasia
- Episodic Primary Myelofibrosis
- Others
- Treatment
- Diagnosis
- Solid
- Liquids
- Others
- Adult
- Child
- Geriatric
- Hospitals
- Clinics
- Others
- United States
- United Kingdom
- Germany
- France
- Italy
- Spain
- Japan
The increasing emphasis on research and development activities by key players is expected to potentially create lucrative opportunities for primary myelofibrosis treatment market growth. Primary myelofibrosis is a rare disease, with an annual incidence of approximately 0.5-1.5 cases per 100,000 individuals in the United States. The incidence rate of myelofibrosis ranged from 0.1 to 1 case per 100,000 per year. The additional market growth can be attributed to the increasing awareness regarding Primary Myelofibrosis (PMF) treatment and the rise in the number of patients is also poised to result in increased production of more effective and targeted treatment drugs and JAK inhibitors.
The healthcare sector has been improving, and favorable government initiatives, reimbursement policies, and changing dietary patterns are collectively contributing to the primary myelofibrosis market growth. These factors, along with the busy lifestyle, are contributing to the growth of the market. Additionally, the market is expected to grow further due to increased investments in research and development activities aimed at developing precise treatments for myelofibrosis in the forecast period.
Geographically, North America is currently dominating the regional market and is expected to drive market growth in the forecast period as well. The market growth is expected to be driven by the increased research and development activities by key players in order to develop more effective and targeted treatment options for the patients, resulting in better patient outcomes. Also, the presence of some of the key players in the region is also propelling the market growth.
Primary Myelofibrosis Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Bristol-Myers Squibb Company
- Amneal Pharmaceuticals, Inc.
- CTI BioPharma Corp
- Actuate Therapeutics Inc.
- Pfizer Inc.
- Galecto
- Incyte Corporation
- AbbVie Inc.
- GlaxoSmithKline plc
- Imago BioSciences
- Sanofi
- F. Hoffmann-La Roche Ltd
- Mylan NV
- Hikma Pharmaceuticals PLC
- Bayer AG
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Table of Contents
350 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Primary Myelofibrosis Overview
- 3.1 Guidelines and Stages
- 3.2 Pathophysiology
- 3.3 Screening and Diagnosis
- 3.4 Treatment Pathway
- 4 Patient Profile
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Primary Myelofibrosis Epidemiology Analysis – 7MM
- 5.1 7MM Epidemiology Scenario Overview (2018-2034)
- 5.2 United States Primary Myelofibrosis Epidemiology Forecast (2018-2034)
- 5.3 EU-4 and United Kingdom Primary Myelofibrosis Epidemiology Forecast (2018-2034)
- 5.3.1 Germany Primary Myelofibrosis Epidemiology Forecast (2018-2034)
- 5.3.2 France Primary Myelofibrosis Epidemiology Forecast (2018-2034)
- 5.3.3 Italy Primary Myelofibrosis Epidemiology Forecast (2018-2034)
- 5.3.4 Spain Primary Myelofibrosis Epidemiology Forecast (2018-2034)
- 5.3.5 United Kingdom Primary Myelofibrosis Epidemiology Forecast (2018-2034)
- 5.4 Japan Primary Myelofibrosis Epidemiology Forecast (2018-2034)
- 6 Primary Myelofibrosis Market Overview – 7MM
- 6.1 Primary Myelofibrosis Market Historical Value (2018-2024)
- 6.2 Primary Myelofibrosis Market Forecast Value (2025-2034)
- 7 Primary Myelofibrosis Market Landscape – 7MM
- 7.1 Primary Myelofibrosis Developers Landscape
- 7.1.1 Analysis by Year of Establishment
- 7.1.2 Analysis by Company Size
- 7.1.3 Analysis by Region
- 7.2 Primary Myelofibrosis Product Landscape
- 7.2.1 Analysis by Products
- 7.2.2 Analysis by Indications
- 7.2.3 Analysis by Route of Administration
- 8 Primary Myelofibrosis Challenges and Unmet Needs
- 8.1 Treatment Pathway Challenges
- 8.2 Compliance and Drop-Out Analysis
- 8.3 Awareness and Prevention Gaps
- 9 Cost of Treatment
- 10 Primary Myelofibrosis Market Dynamics
- 10.1 Market Drivers and Constraints
- 10.2 SWOT Analysis
- 10.3 Porter’s Five Forces Model
- 10.4 Key Demand Indicators
- 10.5 Key Price Indicators
- 10.6 Industry Events, Initiatives, and Trends
- 10.7 Value Chain Analysis
- 11 Primary Myelofibrosis Market Segmentation – 7MM
- 11.1 Primary Myelofibrosis Market by Type
- 11.1.1 Market Overview
- 11.1.2 Spinocerebellar Primary Myelofibrosis
- 11.1.3 Primary Myelofibrosis-Telangiectasia
- 11.1.4 Episodic Primary Myelofibrosis
- 11.1.5 Others
- 11.2 Primary Myelofibrosis Market by Services
- 11.2.1 Market Overview
- 11.2.2 Treatment
- 11.2.3 Diagnosis
- 11.3 Primary Myelofibrosis Market by Dosage Forms
- 11.3.1 Market Overview
- 11.3.2 Solid
- 11.3.3 Liquid
- 11.3.4 Others
- 11.4 Primary Myelofibrosis Market by Age
- 11.4.1 Market Overview
- 11.4.2 Children
- 11.4.3 Adult
- 11.4.4 Geriatric
- 11.5 Primary Myelofibrosis Market by End User
- 11.5.1 Market Overview
- 11.5.2 Hospitals
- 11.5.3 Clinics
- 11.5.4 Others
- 11.6 Primary Myelofibrosis Market by Region
- 11.6.1 Market Overview
- 11.6.2 United States
- 11.6.3 EU-4 and the United Kingdom
- 11.6.3.1 Germany
- 11.6.3.2 France
- 11.6.3.3 Italy
- 11.6.3.4 Spain
- 11.6.3.5 United Kingdom
- 11.6.4 Japan
- 12 United States Primary Myelofibrosis Market
- 12.1 Primary Myelofibrosis Market Historical Value (2018-2024)
- 12.2 Primary Myelofibrosis Market Forecast Value (2025-2034)
- 12.3 Primary Myelofibrosis Market by Disease Type
- 12.4 Primary Myelofibrosis Market by Treatment Type
- 13 EU-4 and United Kingdom Primary Myelofibrosis Market
- 13.1 Primary Myelofibrosis Market Historical Value (2018-2024)
- 13.2 Primary Myelofibrosis Market Forecast Value (2025-2034)
- 13.3 Germany Primary Myelofibrosis Market Overview
- 13.3.1 Primary Myelofibrosis Market by Disease Type
- 13.3.2 Primary Myelofibrosis Market by Treatment Type
- 13.4 France Primary Myelofibrosis Market Overview
- 13.4.1 Primary Myelofibrosis Market by Disease Type
- 13.4.2 Primary Myelofibrosis Market by Treatment Type
- 13.5 Italy Primary Myelofibrosis Market Overview
- 13.5.1 Primary Myelofibrosis Market by Disease Type
- 13.5.2 Primary Myelofibrosis Market by Treatment Type
- 13.6 Spain Primary Myelofibrosis Market Overview
- 13.6.1 Primary Myelofibrosis Market by Disease Type
- 13.6.2 Primary Myelofibrosis Market by Treatment Type
- 13.7 United Kingdom Primary Myelofibrosis Market Overview
- 13.7.1 Primary Myelofibrosis Market by Disease Type
- 13.7.2 Primary Myelofibrosis Market by Treatment Type
- 14 Japan Primary Myelofibrosis Market
- 14.1 Primary Myelofibrosis Market Historical Value (2018-2024)
- 14.2 Primary Myelofibrosis Market Forecast Value (2025-2034)
- 14.2.1 Primary Myelofibrosis Market by Disease Type
- 14.2.2 Primary Myelofibrosis Market by Treatment Type
- 15 Patent Analysis
- 15.1 Analysis by Type of Patent
- 15.2 Analysis by Publication year
- 15.3 Analysis by Issuing Authority
- 15.4 Analysis by Patent Age
- 15.5 Analysis by CPC Analysis
- 15.6 Analysis by Patent Valuation
- 15.7 Analysis by Key Players
- 16 Grants Analysis
- 16.1 Analysis by year
- 16.2 Analysis by Amount Awarded
- 16.3 Analysis by Issuing Authority
- 16.4 Analysis by Grant Application
- 16.5 Analysis by Funding Institute
- 16.6 Analysis by NIH Departments
- 16.7 Analysis by Recipient Organization
- 17 Clinical Trials Analysis
- 17.1 Analysis by Trial Registration Year
- 17.2 Analysis by Trial Status
- 17.3 Analysis by Trial Phase
- 17.4 Analysis by Therapeutic Area
- 17.5 Analysis by Geography
- 18 Funding Analysis
- 18.1 Analysis by Funding Instances
- 18.2 Analysis by Type of Funding
- 18.3 Analysis by Funding Amount
- 18.4 Analysis by Leading Players
- 18.5 Analysis by Leading Investors
- 18.6 Analysis by Geography
- 19 Partnership and Collaborations Analysis
- 19.1 Analysis by Partnership Instances
- 19.2 Analysis by Type of Partnership
- 19.3 Analysis by Leading Players
- 19.4 Analysis by Geography
- 20 Supplier Landscape
- 20.1 Bristol-Myers Squibb Company
- 20.1.1 Financial Analysis
- 20.1.2 Product Portfolio
- 20.1.3 Demographic Reach and Achievements
- 20.1.4 Mergers and Acquisition
- 20.1.5 Certifications
- 20.2 Amneal Pharmaceuticals, Inc.
- 20.2.1 Financial Analysis
- 20.2.2 Product Portfolio
- 20.2.3 Demographic Reach and Achievements
- 20.2.4 Mergers and Acquisition
- 20.2.5 Certifications
- 20.3 CTI BioPharma Corp
- 20.3.1 Financial Analysis
- 20.3.2 Product Portfolio
- 20.3.3 Demographic Reach and Achievements
- 20.3.4 Mergers and Acquisition
- 20.3.5 Certifications
- 20.4 Actuate Inc.
- 20.4.1 Financial Analysis
- 20.4.2 Product Portfolio
- 20.4.3 Demographic Reach and Achievements
- 20.4.4 Mergers and Acquisition
- 20.4.5 Certifications
- 20.5 Pfizer Inc.
- 20.5.1 Financial Analysis
- 20.5.2 Product Portfolio
- 20.5.3 Demographic Reach and Achievements
- 20.5.4 Mergers and Acquisition
- 20.5.5 Certifications
- 20.6 Galecto
- 20.6.1 Financial Analysis
- 20.6.2 Product Portfolio
- 20.6.3 Demographic Reach and Achievements
- 20.6.4 Mergers and Acquisition
- 20.6.5 Certifications
- 20.7 Incyte Corporation
- 20.7.1 Financial Analysis
- 20.7.2 Product Portfolio
- 20.7.3 Demographic Reach and Achievements
- 20.7.4 Mergers and Acquisition
- 20.7.5 Certifications
- 20.8 AbbVie Inc.
- 20.8.1 Financial Analysis
- 20.8.2 Product Portfolio
- 20.8.3 Demographic Reach and Achievements
- 20.8.4 Mergers and Acquisition
- 20.8.5 Certifications
- 20.9 GlaxoSmithKline plc
- 20.9.1 Financial Analysis
- 20.9.2 Product Portfolio
- 20.9.3 Demographic Reach and Achievements
- 20.9.4 Mergers and Acquisition
- 20.9.5 Certifications
- 20.10 Imago BioSciences
- 20.10.1 Financial Analysis
- 20.10.2 Product Portfolio
- 20.10.3 Demographic Reach and Achievements
- 20.10.4 Mergers and Acquisition
- 20.10.5 Certifications
- 20.11 Sanofi
- 20.11.1 Financial Analysis
- 20.11.2 Product Portfolio
- 20.11.3 Demographic Reach and Achievements
- 20.11.4 Mergers and Acquisition
- 20.11.5 Certifications
- 20.12 F. Hoffmann-La Roche Ltd
- 20.12.1 Financial Analysis
- 20.12.2 Product Portfolio
- 20.12.3 Demographic Reach and Achievements
- 20.12.4 Mergers and Acquisition
- 20.12.5 Certifications
- 20.13 Mylan NV
- 20.13.1 Financial Analysis
- 20.13.2 Product Portfolio
- 20.13.3 Demographic Reach and Achievements
- 20.13.4 Mergers and Acquisition
- 20.13.5 Certifications
- 20.14 Hikma Pharmaceuticals PLC
- 20.14.1 Financial Analysis
- 20.14.2 Product Portfolio
- 20.14.3 Demographic Reach and Achievements
- 20.14.4 Mergers and Acquisition
- 20.14.5 Certifications
- 20.15 Bayer AG
- 20.15.1 Financial Analysis
- 20.15.2 Product Portfolio
- 20.15.3 Demographic Reach and Achievements
- 20.15.4 Mergers and Acquisition
- 20.15.5 Certifications
- 21 Primary Myelofibrosis Market - Distribution Model (Additional Insight)
- 21.1 Overview
- 21.2 Potential Distributors
- 21.3 Key Parameters for Distribution Partner Assessment
- 22 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 23 Company Competitiveness Analysis (Additional Insight)
- 23.1 Very Small Companies
- 23.2 Small Companies
- 23.3 Mid-Sized Companies
- 23.4 Large Companies
- 23.5 Very Large Companies
- 24 Payment Methods (Additional Insight)
- 24.1 Government Funded
- 24.2 Private Insurance
- 24.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
